Glenmark Pharmaceuticals Canada Inc. Launches Men’s GLN-Minoxidil 5% w/w Topical Aerosol Foam in Canadian Retail
Strengthens OTC portfolio with affordable hair regrowth solution for Men
CONCORD, Ontario, March 31, 2026 /PRNewswire/ — Glenmark Pharmaceuticals Canada Inc. announced the launch of Men’s GLN-Minoxidil 5% w/w (50 mg/g) Topical Aerosol Foam in Canada, expanding its OTC portfolio with a clinically proven, convenient, and affordable option for men experiencing hair loss (Hair Regrowth Treatment).
GLN-Minoxidil Men’s 5% Foam is a topical treatment formulated with 5% minoxidil, a widely used and clinically established ingredient for supporting hair regrowth in men. The fast-drying, unscented aerosol foam enables precise, no-drip application and quick absorption, offering a convenient alternative to traditional liquid formulations.
With this launch, Glenmark aims to improve access to effective hair loss treatment by introducing a high-quality foam formulation at a competitive price point, addressing both affordability and ease of use – two key barriers to consistent treatment adoption.
The product has already demonstrated early traction in the Canadian e-commerce channel, ranking among the top-selling hair regrowth treatments on Amazon.ca, supported by sustained consumer demand and positive user feedback.
Commenting on the launch, Marc Kikuchi, President & Business Head, North America said « At Glenmark, our focus is on expanding access to high-quality, reliable treatment options that meet evolving patients’ needs. The launch of GLN Minoxidil Men’s 5% Foam reflects our commitment to building a differentiated OTC portfolio by combining efficacy with convenience and affordability. »
Glenmark Pharmaceuticals Canada Inc’s OTC business has recorded consistent growth over the past five years. This launch further strengthens the company’s presence in the category, aligned with a broader strategy of expanding accessible, branded offerings across key markets.
About Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a global, research‐led pharmaceutical company with a unique focus on innovation and accessibility. We pioneer transformative breakthrough therapies that aim to redefine treatment while expanding access to high-quality and affordable medicines for patients around the world. With 11 world-class manufacturing facilities across four continents, supported by six cutting-edge R&D centres, and a commercial footprint in 80+ countries, we deliver a diversified portfolio across branded, innovative, generics, and consumer health products, with a focus on respiratory, dermatology, and oncology. Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024. For more information, visit www.glenmarkpharma.com
Logo – https://mma.prnewswire.com/media/451507/5893583/PRNE_Glenmark_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/glenmark-pharmaceuticals-canada-inc-launches-mens-gln-minoxidil-5-ww-topical-aerosol-foam-in-canadian-retail-302730499.html
